Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

D-β-hydroxybutyrate is protective in mouse models of Huntington's disease.

Lim S, Chesser AS, Grima JC, Rappold PM, Blum D, Przedborski S, Tieu K.

PLoS One. 2011;6(9):e24620. doi: 10.1371/journal.pone.0024620. Epub 2011 Sep 12.

2.

Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.

Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, Hersch SM.

J Neurosci. 2003 Oct 15;23(28):9418-27.

3.

Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.

Jia H, Pallos J, Jacques V, Lau A, Tang B, Cooper A, Syed A, Purcell J, Chen Y, Sharma S, Sangrey GR, Darnell SB, Plasterer H, Sadri-Vakili G, Gottesfeld JM, Thompson LM, Rusche JR, Marsh JL, Thomas EA.

Neurobiol Dis. 2012 May;46(2):351-61.

5.

Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease.

Bizat N, Hermel JM, Boyer F, Jacquard C, Créminon C, Ouary S, Escartin C, Hantraye P, Kajewski S, Brouillet E.

J Neurosci. 2003 Jun 15;23(12):5020-30. Erratum in: J Neurosci. 2003 Oct 29;23(30):9960.

6.
7.

Specific promoter deacetylation of histone H3 is conserved across mouse models of Huntington's disease in the absence of bulk changes.

Guiretti D, Sempere A, Lopez-Atalaya JP, Ferrer-Montiel A, Barco A, Valor LM.

Neurobiol Dis. 2016 May;89:190-201. doi: 10.1016/j.nbd.2016.02.004. Epub 2016 Feb 3.

PMID:
26851501
8.

Striatal pre-enkephalin overexpression improves Huntington's disease symptoms in the R6/2 mouse model of Huntington's disease.

Bissonnette S, Vaillancourt M, Hébert SS, Drolet G, Samadi P.

PLoS One. 2013 Sep 11;8(9):e75099. doi: 10.1371/journal.pone.0075099. eCollection 2013.

9.

Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease.

Acevedo-Torres K, Berríos L, Rosario N, Dufault V, Skatchkov S, Eaton MJ, Torres-Ramos CA, Ayala-Torres S.

DNA Repair (Amst). 2009 Jan 1;8(1):126-36. doi: 10.1016/j.dnarep.2008.09.004. Epub 2008 Nov 20.

10.

Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.

Hansson O, Castilho RF, Korhonen L, Lindholm D, Bates GP, Brundin P.

J Neurochem. 2001 Aug;78(4):694-703.

11.

Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.

Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Muñoz E, Sagredo O.

Neurotherapeutics. 2015 Jan;12(1):185-99. doi: 10.1007/s13311-014-0304-z.

12.

Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation.

Fox JH, Barber DS, Singh B, Zucker B, Swindell MK, Norflus F, Buzescu R, Chopra R, Ferrante RJ, Kazantsev A, Hersch SM.

J Neurochem. 2004 Oct;91(2):413-22.

13.

Histone Deacetylase Inhibitors Protect Against Pyruvate Dehydrogenase Dysfunction in Huntington's Disease.

Naia L, Cunha-Oliveira T, Rodrigues J, Rosenstock TR, Oliveira A, Ribeiro M, Carmo C, Oliveira-Sousa SI, Duarte AI, Hayden MR, Rego AC.

J Neurosci. 2017 Mar 8;37(10):2776-2794. doi: 10.1523/JNEUROSCI.2006-14.2016. Epub 2017 Jan 25.

14.

The effect of Ginkgo biloba extract on 3-nitropropionic acid-induced neurotoxicity in rats.

Mahdy HM, Tadros MG, Mohamed MR, Karim AM, Khalifa AE.

Neurochem Int. 2011 Nov;59(6):770-8. doi: 10.1016/j.neuint.2011.07.012. Epub 2011 Jul 31.

PMID:
21827809
15.

MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms.

Jovicic A, Zaldivar Jolissaint JF, Moser R, Silva Santos Mde F, Luthi-Carter R.

PLoS One. 2013;8(1):e54222. doi: 10.1371/journal.pone.0054222. Epub 2013 Jan 17.

16.

Potential of protease inhibitor in 3-nitropropionic acid induced Huntington's disease like symptoms: mitochondrial dysfunction and neurodegeneration.

Hariharan A, Shetty S, Shirole T, Jagtap AG.

Neurotoxicology. 2014 Dec;45:139-48. doi: 10.1016/j.neuro.2014.10.004. Epub 2014 Oct 16.

PMID:
25445565
17.

Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.

Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, Beal MF.

J Neurochem. 2009 Jun;109(5):1427-39. doi: 10.1111/j.1471-4159.2009.06074.x. Epub 2009 Mar 28.

18.

Probucol increases striatal glutathione peroxidase activity and protects against 3-nitropropionic acid-induced pro-oxidative damage in rats.

Colle D, Santos DB, Moreira EL, Hartwig JM, dos Santos AA, Zimmermann LT, Hort MA, Farina M.

PLoS One. 2013 Jun 14;8(6):e67658. doi: 10.1371/journal.pone.0067658. Print 2013.

19.

Mitochondrial cofactors in experimental Huntington's disease: behavioral, biochemical and histological evaluation.

Mehrotra A, Sandhir R.

Behav Brain Res. 2014 Mar 15;261:345-55. doi: 10.1016/j.bbr.2013.12.035. Epub 2014 Jan 3.

PMID:
24393741
20.

Supplemental Content

Support Center